Mereo BioPharma Group (MPH) Sets New 12-Month Low at $226.00
Mereo BioPharma Group PLC (LON:MPH) hit a new 52-week low during trading on Thursday . The company traded as low as GBX 226 ($2.95) and last traded at GBX 226 ($2.95), with a volume of 310 shares changing hands. The stock had previously closed at GBX 231 ($3.02).
About Mereo BioPharma Group (LON:MPH)
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease.
Featured Article: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter.